TNFRSF17 and plasma cell myeloma: A BCMA/CD3 bispecific T-cell engager (BiTE®, Amgen, Thousand Oaks, CA, USA) antibody (BI836909), which was made based on blinatumomab (Anti-CD19/CD3 BiTE® antibody, Amgen, Thousand Oaks, CA, USA), was tested in a preclinical study using BCMA on myeloma cells as a target and CD3 on T cells as the other target [113].